Open Access

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells

Tanja Mesti

Tanja Mesti

  • Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidouparis, France
  • Division of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Mesti, Tanja
, 
Nadia Bouchemal

Nadia Bouchemal

CSPBAT, UMR 7244, CNRS, Université Paris 13Bobigny, France
Search for this author on
Sciendo|Google Scholar
Bouchemal, Nadia
, 
Claire Banissi

Claire Banissi

Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidouparis, France
Search for this author on
Sciendo|Google Scholar
Banissi, Claire
, 
Mohamed N. Triba

Mohamed N. Triba

CSPBAT, UMR 7244, CNRS, Université Paris 13Bobigny, France
Search for this author on
Sciendo|Google Scholar
Triba, Mohamed N.
, 
Carole Marbeuf-Gueye

Carole Marbeuf-Gueye

CSPBAT, UMR 7244, CNRS, Université Paris 13Bobigny, France
Search for this author on
Sciendo|Google Scholar
Marbeuf-Gueye, Carole
, 
Maja Cemazar

Maja Cemazar

Department of Experimental Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Cemazar, Maja
, 
Laurence Le Moyec

Laurence Le Moyec

Unité de Biologie Intégrative des Adaptations à l’Exercice, Université d’EvryEvry, France
Search for this author on
Sciendo|Google Scholar
Moyec, Laurence Le
, 
Antoine F. Carpentier

Antoine F. Carpentier

  • Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidouparis, France
  • Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service de NeurologieBobigny, France
Search for this author on
Sciendo|Google Scholar
Carpentier, Antoine F.
, 
Philippe Savarin

Philippe Savarin

Department of Experimental Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Savarin, Philippe
 and 
Janja Ocvirk

Janja Ocvirk

Division of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Ocvirk, Janja
  
Nov 26, 2018
Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Nov 26, 2018
Page range: 392 - 398
Received: Nov 30, 2017
Accepted: Oct 21, 2018
DOI: https://doi.org/10.2478/raon-2018-0046
Keywords
© 2018 Tanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Cemazar, Laurence Le Moyec, Antoine F. Carpentier,Philippe Savarin, Janja Ocvirk, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

FIGURE 1

mIDH1-U87 vascular endothelial growth factor (VEGF) secretion and cell viability. (A) VEGF secretion ofmIDH1-U87 cells was assessed with immunoassay (B) Cell viability (%) of mIDH1-U87 cell lines after 72 h bevacizumab treatment at different cell line viability. Concentrations (0.1 mg/mL to 1 mg/mL) was assessed with the MTT assay. Bevacizumab has no significant effect (p > 0.05) on mIDH1-U87 cell line viability.
mIDH1-U87 vascular endothelial growth factor (VEGF) secretion and cell viability. (A) VEGF secretion ofmIDH1-U87 cells was assessed with immunoassay (B) Cell viability (%) of mIDH1-U87 cell lines after 72 h bevacizumab treatment at different cell line viability. Concentrations (0.1 mg/mL to 1 mg/mL) was assessed with the MTT assay. Bevacizumab has no significant effect (p > 0.05) on mIDH1-U87 cell line viability.

FIGURE 2

(A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. 1H CPMG spectrum of cells incubated with bevacizumab (D, RED).
(A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. 1H CPMG spectrum of cells incubated with bevacizumab (D, RED).

Principal discriminant metabolites_ An up arrow (↑) ↓↓ corresponds to an increase of the concentration induced by bevacizumab

Peak numberChemical shift (ppm)AttributionsConcentration variations Induced by Bev
1184/2.24/32OH-glutarate↑20%
23.22GPC/chol↑9%
32.11/2.34/2.55/3 02glutamate↑25%
41.475alanine↑25%
50.88(CH2)n-CH3↑32%
61.28(CH 2)n-CH2-(CH2)m↑20%
72.95creatine↑15%
83.02creatine↑25%
93.2Pcholine↑7%
103.3-3.42Taurine↑30%
113.6glycine↑ND
123.65-3.71GPC↑35%
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed